Clinical Trial

Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study builds on the results of several prior studies that we have been involved with to test the hypothesis that Risk-Adapted De-Intensification of Radiation Therapy and chemotherapy based on HPV subtype, plasma circulating free HPV DNA (cfHPV DNA) level, and cfHPV DNA clearance rate produces Local-Regional Control rates that are similar to what has been achieved with more aggressive therapy in patients with Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma (OPSCC).
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2022-02-24; most recent amendment 2026-04-23.
Status change: Not Yet Recruiting → Recruiting 2022-05-11
Trial Details
NCT Number NCT05268614
Lead Sponsor University of Florida
Collaborators: Naveris, Inc.
Conditions Oropharyngeal Squamous Cell Carcinoma
Enrollment 250 participants
Start Date 2022-05-16
Primary Completion 2029-06 (estimated)
Study Completion 2032-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-24